Graduated in Medicine from Universidade Federal do Rio Grande do Sul (1981) and got his Phd in Pharmacology from the Universidade de São Paulo (1987). At the moment is Full Professor of Pharmacology at the Faculdade de Medicina de Ribeirão Preto, Universidade de São Pauo. Has experience in Pharmacology, focusing on Neuropsicopharmacology, acting on the following subjects: cannabdiol, nitric oxide, anxiety, depression, glutamate and serotonin. He is a member of the Brazilian and São Paulo Academies of Science.javascript:void(0) (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Movements under control |
| Movimientos bajo control |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The need to develop new therapeutic targets for the treatment of neuropsychiatric disorders is a consensus in the scientific literature. Endocannabinoids (eCBs) and nitric oxide (NO) have been proposed as two of these possible targets. Studies from our group have disclosed the therapeutic potential of drugs that interfere with these two atypical neurotransmitters in anxiety, depressive, p…
In the last 15 years our group has contributed to a better understanding of the role of nitric oxide (NO) and endocannabinoids (eCBs) in physiological and pathophysiological processes of the central nervous system. We showed that manipulations of these atypical neurotransmitters are able to change behavioral and autonomic responses of laboratory animals submitted to animal models of anxie…
(Only some records are available in English at this moment)
Interactions between the gut microbiota and the Central Nervous System (CNS) play a significant role in Autism Spectrum Disorder (ASD), highlighting the Gut-Brain-Microbiota Axis as a crucial pathway for understanding this condition. In this regard, there is growing interest in therapeutic approaches for ASD through the manipulation of the microbiota, and this project proposes cannabidiol…
Cannabidiol (CBD) is the most abundant non-psychoactive phytocannabinoid in C. sativa, and there is an extensive bibliography on its mechanisms of action in the body and its effects on neuropsychiatric disorders, such as anxiety and obsessive-compulsive disorder. In clinical studies with CBD, most have identified therapeutic effects at high doses and have been conducted with intraperitone…
Cannabidiol is the main non-psychotomimetic constituent of the Cannabis sativa plant and has broad therapeutic potential for neuropsychiatric disorders, including anxiety and depression. However, the mechanisms involved in these effects have not been fully elucidated yet. In vitro results suggest that, among the different mechanisms described, CBD is capable of inhibiting adenosine uptake…
In the present project we will investigate whether cannabidiol (CBD) could favorably intervene in the long-term behavioral, molecular and inflammatory changes induced by exposure of rats to an intense stress situation called single prolonged stress (SPS). A complementary objective of the proposal is to investigate whether the nitrergic system is involved in these changes, and the impact o…
The need to develop new therapeutic targets for the treatment of neuropsychiatric disorders is a consensus in the scientific literature. Endocannabinoids (eCBs) have been proposed as a possible target, and studies by our group have shown the therapeutic potential of drugs that act on these atypical neurotransmitters in anxiety disorders, depression, psychosis, Parkinson's and neurodegener…
(Only some records are available in English at this moment)
Cannabidiol (CBD), a non-psychotomimetic constituent of Cannabis sativa, has been shown to have various therapeutical effects on neuropsychiatric disorders, including anxiety and depression. However, the molecular mechanisms responsible for these effects have not been fully elucidated. These disorders are associated with alterations in the endocannabinoid system (ECS), which comprises can…
Schizophrenia is a disabling developmental psychiatry disorder that involves alterations in the connectivity between various brain regions. The medial prefrontal cortex (mPFC) and amygdala have reciprocal connections that control their activities. A dysregulation in the connectivity between these brain areas is proposed to play a role in the pathophysiology of SCZ. Abnormalities in neurod…
More than 350 million people worldwide are affected by major depressive disorder (DM), which makes it one of the most prevalent mental illnesses. According to the WHO (World Health Organization, 2017). Brazil is a country with the highest incidence of anxiety and depression in the world and MD will be the second leading cause of disability worldwide. Despite many advances in understanding…
(Only some records are available in English at this moment)
| 14 / 8 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 46 / 21 | Completed scholarships in Brazil |
| 8 / 8 | Completed scholarships abroad |
| 71 / 40 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID